https://www.selleckchem.com/pr....oducts/mito-tempo.ht
Despite advances in treatment, multiple myeloma (MM) remains incurable and results in significant morbidity and mortality. Further research investigating where MM patients die and characterization of end-of-life hospitalizations is needed. We utilized the National Inpatient Sample (NIS) to explore the hospitalization burden of MM patients at the end of their lives. The percent of patients dying in the hospital as a percent of overall MM deaths ranged from 54% in 2002 to 41.4% in 2017 (p 0.01). Blood transfusions were received in